| Entry |
|
|---|
| Name |
First-generation tyrosine kinase inhibitor to ALK fusion
|
|---|
| Definition |
Crizotinib -| (EML4-ALK,CD74/SLC34A2-ROS1) |
|---|
| Expanded |
D09731 -| (238v1,6098v1) |
|---|
| Type |
Drug target
|
|---|
| Gene |
| 238 | ALK; ALK receptor tyrosine kinase |
| 6098 | ROS1; ROS proto-oncogene 1, receptor tyrosine kinase |
|
|---|
| Variant |
|
|---|
| Perturbant |
|
|---|
| Reference |
|
|---|
| Authors |
Mano H |
|---|
| Title |
The EML4-ALK oncogene: targeting an essential growth driver in human cancer. |
|---|
| Journal |
|
|---|
| Reference |
|
|---|
| Authors |
Rothschild SI, Gautschi O |
|---|
| Title |
Crizotinib in the treatment of non--small-cell lung cancer. |
|---|
| Journal |
|
|---|
| LinkDB |
|
|---|
